Premium
Endothelial and Cancer Cells Have Differing Amounts of TGF Beta Receptors Involved in Angiogenesis
Author(s) -
Duffy Iain,
Varacallo Patricia,
Klerk Harrison,
Hawker James
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.554.4
Subject(s) - angiogenesis , endoglin , cancer research , vascular endothelial growth inhibitor , cancer cell , receptor , microbiology and biotechnology , endothelial stem cell , biology , cancer , chemistry , vascular endothelial growth factor a , vascular endothelial growth factor , stem cell , biochemistry , genetics , in vitro , cd34 , vegf receptors
Control of angiogenesis is critical in diseases such as cancer, heart disease, or wound repair. Growth factors such as transforming growth factor beta (TGFß) contribute to angiogenesis and cancer. Multiple TGFß family receptors play a role in tumor function and angiogenesis. We show data that the type I receptor Activin‐Like Kinase 1 and the co‐receptor endoglin can signal in endothelial cells via the TGFß ligand. Others have shown that other ligands such as Bone morphogenetic protein 9 (BMP‐9) and Activin A can also signal through ALK‐1. Further, ALK‐1 and endoglin may also be involved in cell‐cell interactions between endothelial and other cells. We screened endothelial cells and also several cancer cell lines for expression of various TGFß family receptors to begin to understand which receptors may be involved in angiogenesis and interaction of tumor cells with endothelial cells. Endothelial cells show similar expression of ALK‐1, ALK‐5, and endoglin and lower expression of BMP receptor II and TGFßRII. Cancer cells show much lower expression of type II receptors. We are exploring expression and function of TGFß family receptors in angiogenesis and interactions with cancer cells